These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8268459)

  • 21. Platelet-activating factor antagonists (BN 52021 and BN 50730) inhibit tumor necrosis factor-alfa-mediated cytotoxicity on murine L929 tumor cells.
    Hunyadi J; Kenderessy AS; Duda E; Braquet P; Dobozy A
    Mol Immunol; 1993 Apr; 30(6):517-9. PubMed ID: 7683748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Release of eicosanoids in rat peritoneal cavity stimulated with platelet-activating factor (PAF). Effect of the PAF-antagonist BN-52021.
    Jancar S; Braquet P; Sirois P
    Prostaglandins Leukot Essent Fatty Acids; 1989 Jul; 37(1):23-4. PubMed ID: 2548218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet-leukocyte interaction in adhesion to endothelial cells induced by platelet-activating factor in vitro.
    Hirafuji M; Shinoda H
    Br J Pharmacol; 1991 Jun; 103(2):1333-8. PubMed ID: 1884095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enterolobin induces rat paw oedema independently of PAF-acether.
    Castro-Faria-Neto HC; Cordeiro RS; Martins MA; Correia-Da-Silva AC; Bozza PT; Sousa MV; Morhy L
    Mem Inst Oswaldo Cruz; 1991; 86 Suppl 2():129-31. PubMed ID: 1841984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility to platelet-activating factor-induced airway hyperreactivity and hyperpermeability: interstrain variation and genetic control.
    Longphre M; Kleeberger SR
    Am J Respir Cell Mol Biol; 1995 Nov; 13(5):586-94. PubMed ID: 7576695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PAF antagonism as an approach to the treatment of airway hyperreactivity.
    Meade CJ; Heuer H
    Am Rev Respir Dis; 1991 Mar; 143(3 Pt 2):S79-82. PubMed ID: 2003696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PAF induces rat plasma extravasation and releases eicosanoids during anaphylaxis.
    Jancar S; Sirois MG; Carrier J; Braquet P; Sirois P
    Inflammation; 1991 Oct; 15(5):347-54. PubMed ID: 1757122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of Paf antagonists on bronchial hyperresponsiveness induced by Paf, propranolol or indomethacin.
    Dixon EJ; Wilsoncroft P; Robertson DN; Page CP
    Br J Pharmacol; 1989 Jul; 97(3):717-22. PubMed ID: 2758238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of airway narrowing caused by inhaled platelet-activating factor. Role of airway microvascular leakage.
    Tokuyama K; Lötvall JO; Barnes PJ; Chung KF
    Am Rev Respir Dis; 1991 Jun; 143(6):1345-9. PubMed ID: 2048823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of platelet-activating factor on porcine pulmonary blood vessels in vitro.
    Pritze S; Simmet T; Peskar BA
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):495-9. PubMed ID: 1766475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of platelet-activating factor in pancreatitis-associated acute lung injury in the rat.
    Zhou W; McCollum MO; Levine BA; Olson MS
    Am J Pathol; 1992 Apr; 140(4):971-9. PubMed ID: 1562055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PAF-induced amplification of mediator release in septic shock: prevention or downregulation by PAF antagonists.
    Koltai M; Hosford D; Braquet P
    J Lipid Mediat; 1993; 6(1-3):183-98. PubMed ID: 8357981
    [No Abstract]   [Full Text] [Related]  

  • 34. The alkyl-ether phospholipid platelet-activating factor is a stimulator of the hypothalamic-pituitary-adrenal axis in the rat.
    Bernardini R; Calogero AE; Ehrlich YH; Brucke T; Chrousos GP; Gold PW
    Endocrinology; 1989 Aug; 125(2):1067-73. PubMed ID: 2546734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet-activating factor induces the production of leukotrienes by human monocytes.
    Fauler J; Sielhorst G; Frölich JC
    Biochim Biophys Acta; 1989 Sep; 1013(1):80-5. PubMed ID: 2790041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of the specific antagonist of PAF-acether, BN 52021, on the rejection of murine tail skin allografts and the PAF-acether mortality in mice in particular consideration of the role of TXB2.
    Becker K; Lueddeckens G; Braquet P; Förster W
    Prog Clin Biol Res; 1989; 301():499-503. PubMed ID: 2798460
    [No Abstract]   [Full Text] [Related]  

  • 37. Endothelium-dependent effects of platelet-activating factor in the coronary circulation.
    Sagach VF; Zhukova AV; Braquet P
    J Cardiovasc Pharmacol; 1992; 20 Suppl 12():S85-9. PubMed ID: 1282996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence.
    Kubes P; Ibbotson G; Russell J; Wallace JL; Granger DN
    Am J Physiol; 1990 Aug; 259(2 Pt 1):G300-5. PubMed ID: 2166441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of intrastriatal injections of platelet-activating factor and the PAF antagonist BN 52021 on memory.
    Packard MG; Teather LA; Bazan NG
    Neurobiol Learn Mem; 1996 Sep; 66(2):176-82. PubMed ID: 8946410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
    Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
    Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.